Osaka University has identified radiolabeled tyrosine derivatives targeting large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) reported to be useful for the treatment of cancer.
Researchers from Abbvie Inc. recently presented preclinical data for ABBV-706, an SEZ6-targeted topoisomerase 1 (TOP1) inhibitor antibody-drug conjugate (ADC), being developed for the treatment of small-cell lung cancer (SCLC) and other SEZ6-expressing cancers.
Recurium IP Holdings LLC has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-targeting moiety via a linker reported to be useful for the treatment of cancer.
It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented preclinical data for their bispecific antibody (bsAb), IBI-334, against B7-H3 and EGFR.
Kinase inhibitors have emerged as crucial cancer therapeutics due to the involvement of kinases in cancer signaling. At the AACR, Neosome Life Sciences LLC has provided data on their kinase inhibitor NEOS-223 for the potential treatment of tumors. The compound was tested in several cancer cell types, as well as in in vivo cancer models in mice.
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Nectin Therapeutics Ltd. has divulged antibody-drug conjugates (ADCs) comprising a humanized monoclonal antibody targeting poliovirus receptors (PVR; CD155) linked to a cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
